Cargando…

Final Results of the Prospective ADVATE(®) Immune Tolerance Induction Registry (PAIR) Study with Plasma- and Albumin-Free Recombinant Factor VIII

INTRODUCTION: Neutralizing antibodies to coagulation factor VIII (FVIII) remain a major complication associated with FVIII replacement therapy. AIM: To assess safety and efficacy of immune tolerance induction (ITI) therapy with ADVATE(®) (antihemophilic factor [recombinant] [rAHF]) in patients who p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shapiro, Amy D, Fernandez, Alejandro, Teitel, Jerome, Botha, Jaco, Khair, Kate
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612659/ https://www.ncbi.nlm.nih.gov/pubmed/34849043 http://dx.doi.org/10.2147/JBM.S329883

Ejemplares similares

Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE(®)) in the management of hemophilia A
por: Shapiro, Amy D
Publicado: (2007)

Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study
por: Malec, Lynn, et al.
Publicado: (2023)

Extended half‐life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products
por: Teitel, Jerome, et al.
Publicado: (2021)

Efficacy of Octocog Alfa (Advate) in a Child with Type 3 von Willebrand Disease and Alloantibodies
por: Sottilotta, Gianluca, et al.
Publicado: (2017)

Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A
por: Auerswald, Guenter, et al.
Publicado: (2012)

Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study
por: Ettingshausen, Carmen Escuriola, et al.
Publicado: (2023)

Real‐world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A follow‐up retrospective analysis
por: Carcao, Manuel, et al.
Publicado: (2020)

Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?
por: Varthaman, Aditi, et al.
Publicado: (2019)

A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects
por: Blanchette, Victor S., et al.
Publicado: (2021)

Tolerating Factor VIII: Recent Progress
por: Lacroix-Desmazes, Sebastien, et al.
Publicado: (2020)

Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study
por: Nolan, Beatrice, et al.
Publicado: (2020)

Development and Characterization of Recombinant Ovine Coagulation Factor VIII
por: Zakas, Philip M., et al.
Publicado: (2012)

Recombinant factor VIII Fc for the treatment of haemophilia A
por: Hermans, Cedric, et al.
Publicado: (2021)

Modified Factor VIII and Factor IX recombinant products
por: Santagostino, Elena, et al.
Publicado: (2018)

Bacterial Production of Recombinant Coagulation Factor VIII Domains
por: Bashar, Saima, et al.
Publicado: (2023)

Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A
por: Samelson-Jones, Benjamin J., et al.
Publicado: (2020)

Lack of recombinant factor VIII B-domain induces phospholipid vesicle aggregation: implications for the immunogenicity of factor VIII
por: Grushin, K, et al.
Publicado: (2014)

Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice
por: Krishnamoorthy, Sriram, et al.
Publicado: (2015)

Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand
por: Álvarez-Román, María-Teresa, et al.
Publicado: (2023)

N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice
por: Lai, Jesse D., et al.
Publicado: (2018)

A new recombinant factor VIII: from genetics to clinical use
por: Kannicht, Christoph, et al.
Publicado: (2015)

Human coagulation factor VIII domain-specific recombinant polypeptide expression
por: Choi, Su Jin, et al.
Publicado: (2015)

A new recombinant factor VIII: from genetics to clinical use
por: Santagostino, Elena
Publicado: (2014)

Comparative glycosylation mapping of plasma-derived and recombinant human factor VIII
por: Qu, Jingyao, et al.
Publicado: (2020)

Successful Hemostasis with Extended Half-life Recombinant Factor VIII in Circumcision
por: Koç, Başak, et al.
Publicado: (2020)

Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring
por: BJÖRKMAN, S, et al.
Publicado: (2010)

P1619: LOME PILOT STUDY: A MULTICENTER CONTROLLED RANDOMIZED CLINICAL TRIAL OF LOW- VERSUS INTERMEDIATE-DOSE IMMUNE TOLERANCE INDUCTION WITH RECOMBINANT FACTOR VIII (OMFILOCTOCOG ALFA, SCT800) IN CHINA
por: LI, Zengping, et al.
Publicado: (2023)

Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
por: Sherman, Alexandra, et al.
Publicado: (2017)

PROTECT VIII Kids: BAY 94‐9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A
por: Santagostino, Elena, et al.
Publicado: (2020)

Recombinant factor VIII in the management of hemophilia A: current use and future promise
por: Powell, Jerry S
Publicado: (2009)

Potential role of a new PEGylated recombinant factor VIII for hemophilia A
por: Wynn, Tung Thanh, et al.
Publicado: (2016)

Sedimentation Velocity Analytical Ultracentrifugation of Oxidized Recombinant Full-Length Factor VIII
por: Zakas, Philip M., et al.
Publicado: (2020)

Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII
por: Demers, Melanie, et al.
Publicado: (2022)

Dexamethasone promotes durable factor VIII-specific tolerance in hemophilia A mice via thymic mechanisms
por: Georgescu, Maria T., et al.
Publicado: (2018)

Successful immune tolerance induction consisting of high-dose factor VIII rich in von Willebrand factor and pulsed intravenous immunoglobulin: a case report
por: Kubisz, Peter, et al.
Publicado: (2012)

Biochemical and functional characterization of a recombinant monomeric factor VIII–Fc fusion protein
por: PETERS, R T, et al.
Publicado: (2013)

Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy
por: Meeks, Shannon L., et al.
Publicado: (2020)

Recombinant factor VIIa and factor VIII treatment for acquired factor VIII deficiency: a case of repeated thrombotic endotracheal occlusion in a mechanically ventilated patient
por: Lauer, Stefan, et al.
Publicado: (2011)

Cogne VIII
por: CERN. Geneva. SPS-LEAR Experiments Committee
Publicado: (1995)

Enrique VIII
por: Bowle, John
Publicado: (1970)

Cannot write session to /tmp/vufind_sessions/sess_ejd4h5s72vvqabjeno1ethgr73